Activity: Talk or presentation › Oral presentation › Academic
Description
4th thematic: Embryo selection tools and standardisation of treatment addressed to Willem Verpoest
1. The guideline recommends that PGT-A is not recommended for routine clinical use. As an author of an RCT on the topic, do you consider live birth to be the optimal outcome measure for selection-tool interventions such as PGT-A and time-lapse? 2. Other than safety and efficacy, should cost-effectiveness be a factor influencing the adoption of add-on treatments? What is the role of state funding of IVF cycles for the promotion and adoption of add-ons?